G1 Therapeutics announced that the Company has been added to the broad-market Russell 3000 and small-cap Russell 2000 Indexes as of the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets today, Monday, July 1, 2024.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GTHX:
- G1 Therapeutics Added to the Russell 2000® and 3000® Indexes
- G1 Therapeutics price target lowered to $6 from $12 at Needham
- G1 Therapeutics price target lowered to $3 from $9 at H.C. Wainwright
- G1 Therapeutics Reports Setback in Phase 3 Cancer Trial
- G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)